Markets:

Overview

News

Currencies

International

Treasuries

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

12.54 -0.46 (-3.58%)

Delayed Quote Updated: 12:13 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Research

Quarterly Reports Insider Filings Other Filings

All News about 4D Molecular Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

4D Molecular Therapeutics Announces Interim Clinical Data from Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease at NACFC 2022

November 03, 2022

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 27, 2022

Gainers

Via Benzinga

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-710 for Cystic Fibrosis Lung Disease to be Presented at NACFC 2022

October 26, 2022

4D Molecular Therapeutics to host a conference call on November 3rd, 4:30 pm E.T.

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

4D Molecular Shares Fall After Filing For Fabry Disease Trial Amendment ↗

August 12, 2022

Via Benzinga

Kiora Pharma is Starting Human Trials of a Novel Treatment That Could Restore Vision In Patients With Inherited Blindness ↗

September 29, 2022

Kiora Pharmaceuticals Inc. (NASDAQ: KPRX), a pharmaceutical company specializing in treating eye diseases, is moving its drug candidate KIO-301 into a Phase 1b study in the third quarter of this year.

Via Benzinga

Why Twin Vee Powercats Is Trading Lower By Over 30%; Here Are 30 Stocks Moving Premarket ↗

September 29, 2022

Gainers Windtree Therapeutics, Inc (NASDAQ: WINT) rose 50.7% to $0.4827 in pre-market trading after the company said Istaroxime Phase 2 study in early cardiogenic shock was published in the European...

Via Benzinga

4D Molecular Therapeutics Appoints Noriyuki Kasahara, MD, PhD to the Board of Directors and Promotes Fred Kamal, PhD to President and Chief Operating Officer

September 27, 2022

From 4D Molecular Therapeutics, Inc.

Via GlobeNewswire

Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday ↗

August 15, 2022

Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results.

Via Benzinga

Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session ↗

August 12, 2022

Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022 ↗

August 12, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2022 ↗

June 22, 2022

Upgrades

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

June 13, 2022

Via Benzinga

91 Biggest Movers From Friday ↗

June 13, 2022

Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

May 17, 2022

On Tuesday, 123 stocks made new 52-week lows.

Via Benzinga

Looking Into 4D Molecular Therapeutics's Return On Capital Employed ↗

March 29, 2022

Benzinga Pro data, 4D Molecular Therapeutics (NASDAQ:FDMT) reported Q4 sales of $92.00 thousand. Earnings fell to a loss of $25.08 million, resulting in a 12.79% decrease from last quarter.

Via Benzinga

The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale ↗

March 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

4D Molecular Shares Updated Data From Fabry Disease Trial ↗

February 09, 2022

4D Molecular Therapeutics Inc (NASDAQ: FDMT) has posted updated interim data from the Phase 1/2 trial of 4D-310 in Fabry disease at the

Via Benzinga

The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In ↗

February 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

6 Underperforming IPO Stocks To Buy On The Dip ↗

February 04, 2022

Here are six 2021 IPO stocks to buy on the dip, according to Bank of America.

Via Talk Markets

6 Underperforming IPO Stocks To Buy On The Dip ↗

February 04, 2022

The U.S. IPO market was red-hot in 2021. The total number of traditional U.S. IPOs hit its highest level since the dot-com boom in the late 1990s, while total IPO deal value reached record levels last...

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

January 12, 2022

On Wednesday, 41 stocks made new 52-week lows. Facts of Interest About Today's 52-Week Lows: Biogen (NASDAQ:BIIB) was the biggest company by market cap to set a...

Via Benzinga

The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs ↗

January 07, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name...

Via Benzinga

Mid-Afternoon Market Update: Gold Down 1%; A10 Networks Shares Gain Following Q3 Results ↗

October 29, 2021

Toward the end of trading Friday, the Dow traded down 0.03% to 35,721.05 while the NASDAQ fell 0.07% to 15,437.03. The S&P also fell, dropping 0.08% to 4,592.96. The U.S. has...

Via Benzinga

Topics Stocks

Benzinga's Top Ratings Upgrades, Downgrades For January 4, 2022 ↗

January 04, 2022

Upgrades According to Vertical Research, the prior rating for Livent Corp (NYSE:

Via Benzinga

66 Biggest Movers From Friday ↗

November 01, 2021

Gainers Bakkt Holdings, Inc. (NASDAQ: BKKT) shares surged 66.1% to close at $42.52 on Friday on continued volatility after the company recently announced partnerships with...

Via Benzinga

The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs ↗

October 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead, Merck to Study Trodelvy-Keytruda Combo For Breast Cancer Gilead, Inc...

Via Benzinga

30 Stocks Moving in Friday's Pre-Market Session ↗

October 29, 2021

Gainers DBV Technologies S.A. (NASDAQ: DBVT) rose 20.3% to $3.68 in pre-market trading after declining 15% on Thursday. DBV Technologies, disclosed that on Oct. 14, it received...

Via Benzinga

The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children ↗

October 26, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Anaptys Sells Royalties Due On Cancer Drug Jemperli To Sagard For $250M...

Via Benzinga

4D Molecular's Fabry Disease Candidate Shows Early Proof-Of-Concept ↗

October 26, 2021

4D Molecular Therapeutics Inc (NASDAQ: FDMT) has announced interim data from the Phase 1/2 trial of intravenous 4D-310 in Fabry disease patients. The Company said...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Browse News Releases

News Releases Overview

Multimedia Gallery

Multimedia Gallery Overview

Trending Topics

4D Molecular Therapeutics, Inc. - Common Stock (NQ:FDMT)

All News about 4D Molecular Therapeutics, Inc. - Common Stock